REFERENCES
- Jibson M, Tandon R. A summary of research findings on the new antipsychotic drugs. Dir Psychiatry 1996; 16: 1–8, [CSA]
- Kapur S, Zipursky R, Remington G. Clinical and theoretical implications of 5HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286–93, [INFOTRIEVE], [CSA]
- Jeste D V, Okamoto A, Napolitano J, Kane J M, Martinez R A. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150–5, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996; 57(suppl 11)4–11, [INFOTRIEVE], [CSA]
- Arnt J. Pharmacological differentiation of classical and novel antipsychotics. Int Clin Psychopharmacol 1998; 13: S7–14, suppl 3[INFOTRIEVE], [CSA]
- Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50: 873–83, [INFOTRIEVE], [CSA], [CROSSREF]
- Kapur S, Zipursky R, Jones C, Shammi C S, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57: 553–9, [INFOTRIEVE], [CSA], [CROSSREF]
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97, [CSA], [CROSSREF]
- Miranda P J, DeFronzo R A, Califf R M, Guyton J R. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J 2005; 149: 33–45, [INFOTRIEVE], [CSA], [CROSSREF]
- Rothman K, Greenland S. Modern epidemiology. Lippincott-Raven, Philadelphia 1998
- Ghaemi S N, Soldani F. Meta-analysis of observational studies: the case of rapid-cycling bipolar disorder. Acta Psychiatr Scand 2003; 108: 1–3, [PUBMED], [INFOTRIEVE], [CSA]
- Miettinen O S, Cook E F. Confounding: essence and detection. Am J Epidemiol 1981; 114: 593–603, [INFOTRIEVE], [CSA]
- Ghaemi S N, Hsu D. Evidence-based treatment of bipolar disorder. Clinical psychopharmacology: an evidence-based approach, D J Stein, B Lerer. Cambridge University Press, Cambridge 2004
- Keck P J, Reeves K, Harrigan E, Ziprasidone Study Group. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001; 21: 27–35, [INFOTRIEVE], [CSA], [CROSSREF]
- Rothman K J. Epidemiology: an introduction. Oxford University Press, Oxford 2002
- Friedman L M, Furberg C D, DeMets D L. Fundamentals of clinical trials, 3rd ed. Springer-Verlag, New York 1998
- Gregorian R S, Golden K A, Bahce A, Goodman C, Kwong W J, Khan Z M. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002; 36: 1577–89, [INFOTRIEVE], [CSA], [CROSSREF]
- Lieberman J A, Stroup T S, McEvoy J P, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S. Dopamine- and serotonin-receptors in schizophrenia: results of imaging studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999; 249(suppl 4)83–9, [INFOTRIEVE], [CSA]
- Meltzer H, Matsubura S, Lee J. The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390–2, [INFOTRIEVE], [CSA]
- Lieberman J, Kane J, Johns C. Clozapine: clinical evidence of novel effects. Clin Neuropharmacol 1986; 9: 140–1, [CSA]
- Arvanitis L, Miller B. The Seroquel Trial 13 Study Group. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233–46, [INFOTRIEVE], [CSA], [CROSSREF]
- Owens D. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994; 55(suppl 5)29–35, [INFOTRIEVE], [CSA]
- Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-center, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166: 712–26, [PUBMED], [INFOTRIEVE], [CSA]
- Jibson M, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215–28, [INFOTRIEVE], [CSA], [CROSSREF]
- Casey D. Drug-induced movement disorders. Futura, Mount Kisco, NY 1992
- Casey D. Neuroleptic-induced acute dystonia. DSM-IV source book. American Psychiatric Association, Washington, DC 1994; 545–59
- Raja M. Managing antipsychotic-induced acute and tardive dystonia. Drug Saf 1998; 19: 57–72, [INFOTRIEVE], [CSA], [CROSSREF]
- Casey D. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995; 10(suppl 3)105–14, [INFOTRIEVE], [CSA]
- Lieberman J, Tollefson G, Tohen M, Green A, Gur R, Kahn R. Comparative efficacy and safety of atypical and conventional antispychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396–404, [INFOTRIEVE], [CSA], [CROSSREF]
- The scourge of EPS: have atypical antipsychotics solved the problem?. J Clin Psychiatry 2000; 61: 955–62, remark by Juncos J in “Impact of EPS on patients”[CSA]
- Povlssen U, Norig U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985; 71: 176–85, [CSA]
- Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 809–15, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Guille C, Sachs G S, Ghaemi S N. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000; 61: 638–42, [INFOTRIEVE], [CSA]
- Ghaemi S N, Hsu D J, Rosenquist K J, Katzow J J, Goodwin F K. Long-term observational comparison of risperidone and olanzapine in bipolar disorder. Ann Clin Psychiatry 2004; 16: 69–73, [INFOTRIEVE], [CSA]
- Brown E S, Chamberlain W, Dhanani N, Paranjpe P, Carmody T J, Sargeant M. An open-label trial of olanzapine for corticosteroid-induced mood symptoms. J Affect Disord 2004; 83: 277–81, [INFOTRIEVE], [CSA], [CROSSREF]
- Miller del D, McEvoy J P, Davis S M, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005; 80: 33–43, [INFOTRIEVE], [CSA], [CROSSREF]
- Fenton W, Blyler C, Wyatt R, McGlashan T. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 1997; 171: 265–8, [INFOTRIEVE], [CSA]
- Morgenstern H, Glazer W. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50: 723–33, [INFOTRIEVE], [CSA]
- Jeste D. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004; 65(suppl 9)21–4, [INFOTRIEVE], [CSA]
- Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999; 99: 160–70, [INFOTRIEVE], [CSA]
- Beasley C, Dellva M, Tamura R, et al. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23–30, [PUBMED], [INFOTRIEVE], [CSA]
- Jeste D, Lacro J, Bailey A, Rockwell E, Harris M, Caligiuri M. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47: 716–9, [INFOTRIEVE], [CSA]
- Sachdev P, Kruk J. Restlessness: the anatomy of a neuropsychiatric symptom. Aust N Z J Psychiatry 1996; 30: 38–53, [INFOTRIEVE], [CSA]
- Sachdev P, Longragan C. The present status of akathisia. J Nerv Ment Dis 1991; 179: 381–91, [PUBMED], [INFOTRIEVE], [CSA]
- Van Putten T. The many faces of akathisia. Compr Psychiatry 1975; 16: 43–7, [INFOTRIEVE], [CSA], [CROSSREF]
- Ayd F J. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054–60, [INFOTRIEVE], [CSA]
- Van Putten T, May P, Marder S. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984; 41: 1036–9, [INFOTRIEVE], [CSA]
- Cem Atbasoglu E, Schultz S K, Andreasen N C. The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia. J Neuropsychiatry Clin Neurosci 2001; 13: 336–41, [INFOTRIEVE], [CSA]
- Cohen B, Keck P, Satlin A, Cole J. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 1993; 29: 1215–9, [CSA], [CROSSREF]
- Claghorn J, Honigfeld G, Abuzzahab F, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7: 377–84, [INFOTRIEVE], [CSA]
- Ghaemi S N. Mood disorders. Lippincott Williams & Wilkins, Philadelphia 2003
- Sanger T, Lieberman J, Tohen M, Grundy S, Beasley C J, Tollefson G. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156: 79–87, [INFOTRIEVE], [CSA]
- Marder S, McQuade R. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123–6, [INFOTRIEVE], [CSA], [CROSSREF]
- Barnes T. Neuromuscular effects of neuroleptics: akathisia. Adverse effects of psychotropic drugs, J M Kane, J A Lieberman. Guilford, New York 1992; 201–17
- Newman S, Bland R. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239–45, [INFOTRIEVE], [CSA]
- Black D, Fisher R. Mortality in DSM-IIIR schizophrenia. Schizophr Res 1992; 7: 109–16, [INFOTRIEVE], [CSA], [CROSSREF]
- Brown S. Excess mortality of schizophrenia. Br J Psychiatry 1997; 171: 502–8, [INFOTRIEVE], [CSA]
- Hansen B. The metabolic syndrome X. Ann N Y Acad Sci 1999; 892: 1–24, [INFOTRIEVE], [CSA]
- Felker B, Yazel J, Short D. Mortality and medical co-morbidity among psychiatric patients: a review. Psychiatr Serv 1996; 47: 1356–63, [INFOTRIEVE], [CSA]
- Jeste D, Gladsjo J, Lindamer L, Lacro J. Medical comorbidity in schizophrenia. Schizophr Bull 1996; 22: 412–30, [CSA]
- Brown S, Inskip H, Barraclough B. Causes of excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212–7, [INFOTRIEVE], [CSA], [CROSSREF]
- Harris E, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 73: 11–53, [CSA]
- Brown S, Birtwistle L, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697–701, [INFOTRIEVE], [CSA], [CROSSREF]
- Kosten T, Ziedonis T. Substance abuse in schizophrenia. Schizophr Bull 1997; 23: 181–6, [PUBMED], [INFOTRIEVE], [CSA]
- Druss B, Bradford W, Rosenheck R, Radford M, Krumholz H. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001; 58: 565–72, [INFOTRIEVE], [CSA], [CROSSREF]
- NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Heart, Lung, and Blood Institute, Bethesda, MD 1998
- Blackburn G. Weight gain and antipsychotic medication. J Clin Psychiatry 2000; 61(suppl 8)360–442, [CSA]
- Wilson P, D'Agostino R, Sullivan L, Parise H, Kannel W. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 1867–72, [INFOTRIEVE], [CSA], [CROSSREF]
- Stevens J, Cai J, Pamuk E, Williamson D, Thun M, Wood J. The effect of age on the association between body mass index and mortality. N Engl J Med 1998; 338: 1–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Casey D, Haupt D, Newcomer J, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65(suppl 7)4–18, [INFOTRIEVE], [CSA]
- Taylor D, McAskill R. Atypical antipsychotics and weight gain—a systematic review. Acta Psychiatr Scand 2000; 101: 416–32, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Meyer J. Effects of atypical antipsychotics on weight gain and serum lipids. J Clin Psychiatry 2001; 62(suppl 27)27–34, [INFOTRIEVE], [CSA]
- Allison D, Casey D, Heo M, et al. Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96, [PUBMED], [INFOTRIEVE], [CSA]
- Bustillo J, Buchanan R, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153: 817–9, [INFOTRIEVE], [CSA]
- Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 2003; 23(suppl 1)21–6, [CSA], [CROSSREF]
- Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001; 62(suppl 23)5–12, [INFOTRIEVE], [CSA]
- Wirshing D, Wirshing W, Kysar L, et al. Novel antipsychotic: a comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358–63, [INFOTRIEVE], [CSA]
- Blin O, Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001; 62(suppl 7)11–21, [INFOTRIEVE], [CSA]
- Nemeroff C. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997; 58(suppl 10)45–9, [INFOTRIEVE], [CSA]
- Brecher M, Rak I, Melvin K, Jones A. The long-term effect of quetiapine monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000; 4: 287–91, [CSA], [CROSSREF]
- Kasper S, Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000; 1: 783–801, [INFOTRIEVE], [CSA], [CROSSREF]
- Brecher M, Geller W. Weight gain with risperidone. J Clin Psychopharmacol 1997; 17: 435–43, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Csernansky J, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16–22, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Allison D, Casey D. Antipsychotic induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62(suppl 7)22–31, [INFOTRIEVE], [CSA]
- Kane J, Carson W, Saha A, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763–71, [PUBMED], [INFOTRIEVE], [CSA]
- Kinon B J, Basson B R, Gilmore J A, Tollefson G D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92–100, [INFOTRIEVE], [CSA]
- Schmoor C, Sauerbrei W, Schumacher M. Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med 2000; 19: 441–52, [INFOTRIEVE], [CSA], [CROSSREF]
- Lindenmayer J, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290–306, [INFOTRIEVE], [CSA], [CROSSREF]
- Gaulin B, Markowitz J, Caley C, Nesbitt L, Dufresne R. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156: 1270–2, [INFOTRIEVE], [CSA]
- Ghaeli P, Dufresne R. Elevated serum triglycerides in clozapine resolve with risperidone. Pharmacotherapy 1995; 15: 382–5, [CSA]
- Koro C, Fedder D, L'Italien G, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59: 1021–6, [INFOTRIEVE], [CSA], [CROSSREF]
- Melkerson K, Hulting A, Brismar K. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychosis. J Clin Psychiatry 2000; 10: 742–9, [CSA]
- Meyer J. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369–74, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Henderson D C, Cagliero E, Copeland P M, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62: 19–28, [INFOTRIEVE], [CSA], [CROSSREF]
- Seroquel. Package insert. AstraZeneca Pharmaceuticals, Wilmington, DE 2003
- Meyer J, Koro C. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1–17, [INFOTRIEVE], [CSA], [CROSSREF]
- Nasrallah H, Newcomer J. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 24(suppl)S7–14, [INFOTRIEVE], [CSA], [CROSSREF]
- Kingsbury S, Fayek M, Trufasiu D, Zada J, Simpson G. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001; 629: 347–9, [CSA]
- Goodnick P, Jerry J. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 2002; 3: 1773–81, [INFOTRIEVE], [CSA], [CROSSREF]
- Dixon L, Weidan P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenic samples. Schizophr Bull 2000; 26: 903–12, [INFOTRIEVE], [CSA]
- Mukherjee S, Decona P, Bocola V, Saraceni F, Scapicchio P. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68–73, [INFOTRIEVE], [CSA], [CROSSREF]
- Cassidy F, Ahearn E, Carrol J. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999; 156: 1417–20, [INFOTRIEVE], [CSA]
- Allison D, Fontaine K, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60: 215–20, [INFOTRIEVE], [CSA]
- Gopalaswamy A, Morgan R. Too many chronic mentally disabled patients are too fat. Acta Psychiatr Scand 1985; 72: 254–8, [INFOTRIEVE], [CSA]
- Kelly C, McCreadie R. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999; 156: 1751–7, [INFOTRIEVE], [CSA]
- Lorenz W. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 1922; 8: 184–96, [CSA]
- Braceland F, Meduna L, Vaichulis J. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945; 102: 108–10, [CSA]
- Langfeldt G. The insulin tolerance test in mental disorders. Acta Psychiatr Neurol Scand Suppl 1952; 80: 189–99, [INFOTRIEVE], [CSA]
- Freeman H. Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psychiatry 1945; 56: 74–8, [CSA]
- Richter D. Biochemical aspects of schizophrenia. Schizophrenia: somatic aspects, D Richter. Pergamon, London 1957
- Muhkerjee S, Roth S, Sanyk R, Schnur D. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Res 1989; 29: 17–27, [CSA], [CROSSREF]
- Sernyak M, Leslie D, Alarcon R, Losonczy M, Rosenheck R. Association of diabetes mellitus with the use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561–6, [PUBMED], [INFOTRIEVE], [CSA]
- Newcomer J, Haupt D, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337–45, [INFOTRIEVE], [CSA]
- Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Medicine 2001; 111: 716–23, [CSA], [CROSSREF]
- Koller E, Doraiswamy P. Olanzapine-associated diabetes. Pharmacotherapy 2002; 22: 841–52, [INFOTRIEVE], [CSA], [CROSSREF]
- Koller E, Cross J, Doraiswamy P, Schneider B. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003; 23: 735–44, [INFOTRIEVE], [CSA], [CROSSREF]
- Jin H, Meyer J, Jeste D. Phenomenology of and risk factors for new onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002; 14: 59–64, [INFOTRIEVE], [CSA], [CROSSREF]
- Cohn T, Remington G, Kameh H. Hyperinsulinemia in psychiatric patients treated with olanzapine. J Clin Psychiatry 2002; 63: 75–6, [INFOTRIEVE], [CSA]
- Abilify. Package insert. Bristol-Meyers Squibb, Princeton, NJ 2003
- Geodon. Package insert. Pfizer, New York 2002
- Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601, [CSA]